Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN1908 · 1 trial · 1 indication
Assessed using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale, a 0-4 point scale where 0= none and 4= incapacitating itch, 0.5 unit increments
| Arm | Type | Description |
|---|---|---|
| REGN1908-1909 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REGN1908 | DRUG | Administered per the protocol |
| REGN1909 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Documented or participant-reported history of moderate to severe cat allergy for at least 2 years with bothersome ocular symptoms being near cat(s) 2. Positive SPT with cat allergen extract (mean wheal diameter at least 5 mm greater than the negative control) at screening...
REGN1908 is an investigational small molecule being developed by Regeneron Pharmaceuticals for the treatment of allergic conjunctivitis, specifically in adult participants with cat allergy. It is currently in Phase 3 clinical development, though the single completed trial did not lead to an approved indication.
REGN1908 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting clinical trials to evaluate the drug's efficacy in reducing ocular allergy signs and symptoms.
REGN1908 is in Phase 3 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 3 trial has been completed, but the drug remains in clinical development and is not yet available for commercial use.
REGN1908 has been studied in one clinical trial, identified as NCT06602726. This Phase 3, randomized, double-blind, placebo-controlled study enrolled 64 adult participants with cat allergy and allergic conjunctivitis. The trial was conducted in the United States and Canada and has been completed.
REGN1908 is part of a combination product referred to as REGN1908-1909 in the clinical trial NCT06602726. The study evaluates the combination of REGN1908 and REGN1909, though REGN1908 is listed as the primary drug name in the development program.